LQDA: Hikma Ruling Reflects Our Base Case Assumption - We Think Yutrepia Will Keep PAH Even in the Worst Case Scenario

Research evidence excerpt

LQDA: Hikma Ruling Reflects Our Base Case Assumption - We Think Yutrepia Will Keep PAH Even in the Worst Case Scenario

Liquidia Corporation Equity Research

Clients of WFS Research are permitted to store, display, analyze, modify, reformat, copy, duplicate and reproduce this report and the information contained

within it for their own internal use and for no other purpose. Without the prior written consent of Wells Fargo Securities, no part of this report may be copied,

duplicated or reproduced in any form by any other means. In addition, this report and its contents may not be redistributed or transmitted to any other party in

whole or in part, directly or indirectly, including by means of any AI Technologies (defined below) through which this report or any portion thereof may be accessible

by any third-party. “AI Technologies” means any deep learning, machine learning, and other artificial intelligence technologies, including without limitation any

and all (a) proprietary algorithms, software, or systems that make use of or employ neural networks, statistical learning algorithms (such as linear and logistic

regression, support vector machines, random forests or k-means clustering) or reinforcement learning, or curated data sets accessible by any of the foregoing or (b)

proprietary embodied artificial intelligence and related hardware or equipment.

In addition, certain text, images, graphics, screenshots and audio or video clips included in this report are protected by copyright law and owned by Wells Fargo

Securities, its affiliates or one or more third parties (collectively, “Protected Content”). Protected Content is made available to clients by Wells Fargo under license

or otherwise in accordance with applicable law.